Search Results - therapeutics+%3e+oncology+%3e+oncology+immunotherapy

39 Results Sort By:
Sonicated Osteoclasts as Drugs to Increase NK Expansion and Function in Patients and in Manufacturing of NK Cells (Case No. 2024-272)
UCLA researchers from the Department of Dentistry have developed an innovative method to manufacture, expand and improve the function of natural killer cells by using sonicated osteoclasts for cancer immunotherapy. BACKGROUND: Natural killer cells (NK cells) are immune cells that recognize and combat pathogens and cancer cells. NK cell immunotherapy...
Published: 10/23/2025   |   Inventor(s): Anahid Jewett
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy
Curative Locoregional Therapy Using Ablation or Catheter-Based Embolization of Targeted Hepatocellular Carcinoma by Delivering Supercharged NK Cells and CAR-NK or CAR-T Cells (UCLA Case No. 2023-115)
UCLA researchers in the School of Dentistry and Interventional Radiology have developed a groundbreaking curative treatment for hepatocellular carcinoma that combines locoregional therapy, such as ablation or catheter-based embolization, with targeted delivery of supercharged NK cells and CAR-NK or CAR-T cells, offering a highly effective approach that...
Published: 10/23/2025   |   Inventor(s): Anahid Jewett, Steven Raman, Jason Chiang
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy
Synthetic Cannabinoid WIN 55,212-2 Increased the Cytotoxicity of NK Cells and IFN-gamma Secretion Ability of Immune Cells in Humanized BLT Mouse Model (UCLA Case No. 2022-281)
UCLA researchers in the School of Dentistry have developed novel strategies synergizing the anti-tumor effects of a synthetic cannabinoid, cytokine, and probiotic bacteria to augments NK cell mediated functions and target a wide variety of cancers and viral infections. BACKGROUND: Interest in the use of synthetic cannabinoids for the treatment of disease...
Published: 10/23/2025   |   Inventor(s): Anahid Jewett
Keywords(s):  
Category(s): Platforms > Drug Delivery, Therapeutics > Oncology > Oncology Immunotherapy
Combination of Insulin-like Growth Factor-1 Receptor (IGF1R) or Insulin Receptor Inhibitors with Immune Checkpoint Inhibitors in Management of Triple-Negative Breast Cancer (UCLA Case No. 2020-872)
UCLA researchers in the Department Joe C. Wen School of Nursing have developed a novel targeted therapy for triple-negative breast cancer with a potential synergy with immunotherapy. BACKGROUND: Triple-negative breast cancer (TNBC) accounts for about 10-15% of women with breast cancer (BC), but its mortality rate is disproportionally high, causing...
Published: 10/6/2025   |   Inventor(s): Nalo Hamilton
Keywords(s):  
Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Metabolism And Endocrinology, Diagnostic Markers > Cancer
Self-Amplifying RNA Form of a Constitutively-Active Sting Protein for Enhancing T-Cell Response to Antigen-Presenting Cells (UCLA Case No. 2020-771)
UCLA researchers in the Department of Chemistry and Biochemistry have developed a novel method for delivering RNA to induce an immune response to cancer cells. BACKGROUND: Cancer therapy continues to remain a challenge despite improvements in detection and clinically available therapies. Recently, improvements to this field have been mainly in the...
Published: 10/22/2025   |   Inventor(s): William Gelbart
Keywords(s): Adenoviridae
Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Diagnostic Markers > Targets And Assays
In Vivo CAR-T-Cell Transformation Using mRNA-Containing in Vitro Reconstituted Virus-Like Particles (UCLA Case No. 2024-057)
Contact UCLA Technology Development Group to learn more. More info available soon.
Published: 10/15/2025   |   Inventor(s): William Gelbart
Keywords(s):  
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy
Methods to Improve Chimeric Antigen Receptor (CAR)-T Cell Efficacy Through Rational Sequence and Structural Modifications (UCLA Case No. 2020-497)
UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed novel engineering methodologies for CAR molecules that overcome the tonic signaling process that leads to T cell exhaustion and poor therapy efficacy. Background: Immunotherapy has become a highly effective method to combat cancer that enhances a...
Published: 7/31/2025   |   Inventor(s): Yvonne Chen
Keywords(s): Cancer Immunotherapy
Category(s): Therapeutics > Oncology > Oncology Immunotherapy
Functional Enrichment and Purification of a Therapeutically Superior Population of Cells (Case No. 2024-024)
Summary: UCLA researchers in the Departments of Bioengineering and Biological Chemistry have developed a method for identifying and enriching therapeutically useful cell sub-populations based on their secretions (SEC-seq). Background: Cell function is defined by a myriad of biomolecules that they secrete; over 3 thousand proteins are estimated to...
Published: 3/3/2025   |   Inventor(s): Dino Di Carlo, Kathrin Plath, Shreya Udani, Justin Langerman
Keywords(s): Cell Surface Receptor, Cytometry, Flow Cytometry, Functional Genomics, High-Throughput Screening, hydrogel, Microfluidics, single cell analysis, Therapeutics
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Life Science Research Tools, Life Science Research Tools > Research Methods, Diagnostic Markers > Targets And Assays, Therapeutics > Cell Therapy
Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)
UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...
Published: 7/17/2025   |   Inventor(s): Cun Yu Wang, Jia Lingfei
Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor
Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing
Targeting Prostate Cancer with a Novel T-Cell Receptor and Tissue-Specific Cancer Antigens for Improved Immune Response (UCLA Case No. 2022-070)
Researchers from UCLA’s Department of Microbiology, Immunology, & Molecular Genetics (MIMG), and the department of Molecular and Medical Pharmacology have identified a set of tissue-specific antigens which have been used to isolate and characterize a group of novel T-cell receptors (TCRs) which target prostate cancer specifically. Furthermore,...
Published: 7/31/2025   |   Inventor(s): Owen Witte, Zhiyuan Mao, Jami Witte, Pavlo Nesterenko, John Lee
Keywords(s): Cancer, cancer antigen, Peptide, peptides, prostate cancer, protein, t-cells
Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
1 2 3 4